| lisdexamfetamine / Generic mfg. |
NCT00556296: Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD |
|
|
| Completed | 3 | 297 | US | NRP104, NRp104, Placebo | New River Pharmaceuticals, Shire | Attention Deficit Hyperactivity Disorder | | 09/05 | | |
NCT00334880: Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 420 | US | NRP104 | New River Pharmaceuticals | Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders | | 11/06 | | |
NCT00337285: An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 349 | US | Vyvanse (lisdexamfetamine dimesylate), NRP104 | New River Pharmaceuticals, Shire | Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders | 11/07 | 06/08 | | |
NCT01000064: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits |
|
|
| Terminated | 3 | 22 | US | Vyvanse, fMRI, functional magnetic resonance imaging, Placebo | Vanderbilt University, Shire | Traumatic Brain Injury, Attention Deficit Disorder | 12/13 | 05/15 | | |
NCT02555150: A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD |
|
|
| Completed | 3 | 40 | US | PRC-063, lisdexamfetamine dimesylate, Placebo | Rhodes Pharmaceuticals, L.P., Purdue Pharma LP | Attention Deficit Hyperactivity Disorder | 01/17 | 01/17 | | |
